Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. 
Our proprietary ALEMBIC™ drug discovery platform is based on a synergy between sophisticated computational and chemistry strategies.

This hybrid platform enables the discovery and development of novel first-in-class engineered small molecules, such as prodrugs, designed to selectively target senescent cells, which play a key role in the progression of chronic disorders.

The first product line developed by Rubedo labs is based on engineered molecules that can selectively target a population of pro-inflammatory and pro-fibrotic cells called “Senescent Cells” that accumulate in the body with age and diseases. These senescent cells cause increased chronic inflammation, pain, and tissue decay that contribute to age-related diseases such as Pulmonary Diseases,  Diabetes, Alzheimer’s, Cardio-Vascular Diseases and Cancer.

By selectively clearing the body and tissues of these cells, while preserving adjacent healthy cells, the tissues can rejuvenate again and diseases revert to improved healthy states.


Rubedo’s proprietary ALEMBIC™ drug discovery platform has developed a novel pipeline of therapeutic candidates which selectively target senescent, pro-inflammatoray, and pro-fibrotic cell populations that result from a variety of cellular stress and damage. Any cells in the human body can become “senescent” over time. 

While in this irreversible senescence state cells remain metabolically active but stop replicating and growing. Senescent cells release cytokines and other toxins into the bloodstream, driving chronic inflammation, which plays a key role in chronic disease progression such as fibrosis or increasing cancer metastasis and tumor growth.



Older or sick people exposed to toxic and aging factors such as pollution, smoking, viruses and infections, develop a number of often lethal respiratory conditions. By rejuvenating lung tissues with our targeted strategy that treat the biological drivers of these pathologies our treatments may prevent the dramatic consequences of these degenerative diseases.

Rubedo lead candidates are designed to treat respiratory diseases with significant unmet needs, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary diseases (COPD)


As a result of many cancer standard of care treatments (such as chemotherapy and radiotherapy), tissues in the body accumulate a large number of senescent cells. The pro-inflammatory environment created by senescent cells promotes tissue decay and the inherent toxicity of the cancer treatments create additional side effects. Patients struggle with longer recovery and higher morbidity following conventional therapies. 

Rubedo is developing a program in pre-clinical stage for unmet clinical needs aimed to selectively clear from the body senescent and cancer cells at the same time. These novel therapies will offer higher efficacy, reduced toxicity and fewer side effects compared to traditional therapies. As a result, patients will experience more effective treatments, improved recovery and a higher quality of life.



Frailty is a common geriatric syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults. Frailty is a condition associated with aging, that has been recognized for centuries. 

Rubedo is developing small molecules that target age-associated senescent cells. These cells accumulate during aging in every tissue of the body and are the foundation for chronic inflammation which leads to tissue decay. By systematically clearing senescent cells in the elder population we intend to prevent the onset of Frailty Syndrome and reverse its effects in people already suffering from it, restoring a healthy and youthful quality of life.



An additional focus area in the discovery phase pipeline includes targeting cell types other than senescence cells, such as stem cells, to activate their regenerative potential that are often progressively lost with age and diseases.

Certain stem cells respond to the pathological changes that occur in the tissue environment and they alter their function from pro-regenerative to pro-fibrotic. By targeting the disfunctional stem cells that emerge in aged and diseased tissues we can support the healthy stem cells to regenerate and repair the tissue and return to a healthy state.

Silicon Valley, CA, USA

Copyright 2020 by Rubedo Life Sciences, inc